Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2015

View Archived Issues

Scientists report new data on the expression of PD-1 and its ligands in MPM

Novel mutations linked to retinitis pigmentosa

Elite Pharmaceuticals and Epic Pharma enter into agreement for abuse-deterrent ELI-200

SAGE-547 eliminates postpartum depression in exploratory trial

Dosing for bone marrow chemoprotection studied with G1T28

Merck KGaA, Illumina and Genea establish Global Fertility Alliance

PEP-Therapy and CleveXel Pharma partner on development of targeted therapy in oncology

NeuPharma begins phase I trial of RX-108

Imaging agent 68Ga-NOTA-NFB found safe in volunteers and patients with glioma

Lycera and Celgene establish strategic collaboration

Mutations in MSDF8 linked to macular dystrophy

The State University of New York patents antituberculosis benzimidazoles

Lilly discloses DGAT2 inhibitors

PTC Therapeutics introduces BMI-1 inhibitors

Pharmakea patents autotaxin inhibitors

Bristol-Myers Squibb discloses EZH2 inhibitors

Selecta Biosciences begins phase I program of SEL-212 for gout

FDA grants orphan drug designation to Isarna's ISTH-0036

Goodwin partners with Aspyrian on GMP manufacturing of RM-1929

FDA awards orphan drug designation to AG-120 for AML

U.S. orphan drug designation awarded to LN-144 for malignant melanoma

Arrowhead's ARC-AAT obtains FDA orphan drug designation for AATD-associated liver disease

BMS selects drug candidate from PeptiDream discovery collaboration

Roche receives FDA breakthrough therapy designation for Actemra in systemic sclerosis

Experiments support weekly administration of long-acting insulin product AB-101 for diabetes

Ziarco's ZPL-389 enters phase IIa trial in patients with atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...